One could speculate that the combination of CCR2/5 antagonists with a metabolic, antisteatotic drug (such as an FGF21 agonist) can improve NASH and fibrosis in human patients more effectively than either drug alone [34], as we have shown in this study using a fibrotic NASH mouse model. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.